Amphastar’s lawyer wants the Appellate Court to interpret batch testing as a pre-FDA-approval activity in order to claim that the pre-FDA-approval safe harbor applies, which is quite a stretch, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”